Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO

Booking.com

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study of ADC-1013 (JNJ-7107) at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4. The study results show that side effects were generally mild and transient.

The primary aim of the study was safety and to establish a recommended dose for Phase II. The study is still ongoing and has enrolled a total of 95 patients. The maximum tolerated dose has not yet been reached. Doses up to 1200 μg/kg i.v without

Booking.com

Source: Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.